Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin 

Microsoft Excel

Two-Component Disaggregation of ROE

Regeneron Pharmaceuticals Inc., decomposition of ROE

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2024 15.03% = 11.69% × 1.29
Dec 31, 2023 15.22% = 11.95% × 1.27
Dec 31, 2022 19.14% = 14.85% × 1.29
Dec 31, 2021 43.03% = 31.75% × 1.36
Dec 31, 2020 31.86% = 20.47% × 1.56

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Return on Assets (ROA)
The Return on Assets exhibited a notable increase from 20.47% in 2020 to a peak of 31.75% in 2021. However, following this peak, there was a marked decline over the subsequent years, decreasing to 14.85% in 2022 and further tapering to approximately 11.7% by 2024. This pattern suggests an initial enhancement in asset utilization efficiency that was not sustained in later periods.
Financial Leverage
The Financial Leverage ratio showed a decreasing trend from 1.56 in 2020 to a lower level around 1.27-1.29 in the years 2023 and 2024. This indicates a gradual reduction in the company's use of debt relative to equity over the analyzed timeframe, pointing to a possible deleveraging strategy or a shift towards greater equity financing.
Return on Equity (ROE)
Return on Equity followed a pattern similar to the ROA, rising sharply from 31.86% in 2020 to a maximum of 43.03% in 2021. Thereafter, ROE declined significantly, dropping to 19.14% in 2022 and continuing downward to around 15% by 2023-2024. This decline in ROE alongside decreased leverage suggests that the reduced profitability is driven more by operational performance than by changes in capital structure.

Three-Component Disaggregation of ROE

Regeneron Pharmaceuticals Inc., decomposition of ROE

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2024 15.03% = 31.07% × 0.38 × 1.29
Dec 31, 2023 15.22% = 30.14% × 0.40 × 1.27
Dec 31, 2022 19.14% = 35.64% × 0.42 × 1.29
Dec 31, 2021 43.03% = 50.25% × 0.63 × 1.36
Dec 31, 2020 31.86% = 41.35% × 0.50 × 1.56

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Net Profit Margin
The net profit margin exhibited a peak in 2021 at 50.25%, followed by a significant decline to 35.64% in 2022. This downward trend continued through 2023, reaching 30.14%, with a slight recovery to 31.07% in 2024. Overall, profit margins have decreased from the high point in 2021 but remained above the 2020 baseline.
Asset Turnover
Asset turnover showed an increase from 0.5 in 2020 to 0.63 in 2021, indicating improved efficiency in using assets to generate revenue. However, from 2022 onward, the ratio steadily declined to 0.42, then 0.4, and further to 0.38 by 2024. This suggests a gradual decrease in asset utilization efficiency after 2021.
Financial Leverage
Financial leverage steadily decreased from 1.56 in 2020 to 1.27 in 2023, implying a reduction in the use of debt relative to equity over this period. In 2024, the leverage ratio increased slightly to 1.29, indicating a minor uptick in leverage but remaining at a relatively low level compared to earlier years.
Return on Equity (ROE)
Return on equity experienced a strong rise from 31.86% in 2020 to a high of 43.03% in 2021. However, this was followed by a sharp decline in 2022 to 19.14%, continuing downward to 15.22% in 2023 and slightly lower to 15.03% in 2024. Despite the decrease after 2021, ROE remains positive but notably diminished compared to the peak.
Overall Summary
The period analyzed reveals a peak in profitability and efficiency metrics around 2021, followed by declines in net profit margin, asset turnover, and return on equity in subsequent years through 2024. Financial leverage showed a trend of deleveraging until 2023, with a minor increase in 2024. The patterns suggest that while the company achieved high profitability and efficiency in 2021, maintaining these levels proved challenging in later years, with a shift towards lower returns and asset utilization efficiency, accompanied by reduced financial leverage.

Five-Component Disaggregation of ROE

Regeneron Pharmaceuticals Inc., decomposition of ROE

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2024 15.03% = 0.92 × 0.99 × 34.05% × 0.38 × 1.29
Dec 31, 2023 15.22% = 0.94 × 0.98 × 32.57% × 0.40 × 1.27
Dec 31, 2022 19.14% = 0.89 × 0.99 × 40.40% × 0.42 × 1.29
Dec 31, 2021 43.03% = 0.87 × 0.99 × 58.38% × 0.63 × 1.36
Dec 31, 2020 31.86% = 0.92 × 0.99 × 45.51% × 0.50 × 1.56

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The financial data reveals several notable trends over the analyzed periods. The tax burden ratio exhibited slight fluctuations, starting at 0.92, dipping to 0.87 in the next period, and later returning to near its initial level around 0.92. This suggests relative stability in the effective tax rate with minor variations.

The interest burden ratio remained consistently high and stable across all periods, maintaining values close to 0.99. This indicates minimal impact from interest expenses on earnings before interest and taxes, reflecting effective management of interest-related costs.

The EBIT margin experienced significant volatility. It peaked at 58.38% before declining sharply to 40.4%, followed by further decreases to the low 30% range. This downward trend indicates margin compression, possibly due to increased operating costs or pricing pressures.

Asset turnover showed a declining pattern, starting at 0.5 and decreasing to 0.38 over the period. This decline reflects a reduction in the efficiency with which assets are used to generate sales, suggesting potential challenges in asset utilization or sales growth lagging behind asset increases.

Financial leverage decreased from 1.56 initially to around 1.27-1.29 in later periods, indicating a gradual reduction in reliance on debt financing relative to equity. This trend could point to a more conservative capital structure or repayments of debt.

Return on equity (ROE) showed a marked decline, peaking at 43.03% early on before dropping steeply to around 15% in the latest periods. The decline in ROE aligns with the decreases in EBIT margin and asset turnover, suggesting lower profitability and efficiency in generating returns for shareholders.

Summary:
Overall, the data points to decreasing profitability and efficiency, with EBIT margins and asset turnover ratios contracting over time. While leverage has been reduced moderately, the declining ROE signals a diminished capacity to generate returns on equity. Stability in tax and interest burdens suggests no significant changes in tax policy or interest expense influence. The trends highlight potential areas for management focus on improving operational efficiency and profitability.

Two-Component Disaggregation of ROA

Regeneron Pharmaceuticals Inc., decomposition of ROA

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2024 11.69% = 31.07% × 0.38
Dec 31, 2023 11.95% = 30.14% × 0.40
Dec 31, 2022 14.85% = 35.64% × 0.42
Dec 31, 2021 31.75% = 50.25% × 0.63
Dec 31, 2020 20.47% = 41.35% × 0.50

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Net Profit Margin
The net profit margin displayed an overall fluctuating trend over the five-year period. It peaked in 2021 at 50.25%, indicating a strong profitability during that year. However, there was a subsequent decline in the following years, dropping to 35.64% in 2022 and further reducing to around 30% in 2023 and 2024. Despite this decrease, the margin remained above 30% in the last two years, reflecting a relatively solid profit generation capability.
Asset Turnover
The asset turnover ratio showed a downward trend over the entire timeframe. Starting from 0.5 in 2020, it increased to 0.63 in 2021, indicating improved efficiency in using assets to generate revenue. Afterward, it declined progressively each year to 0.42 in 2022, 0.4 in 2023, and 0.38 in 2024. This trend suggests a reduction in asset utilization efficiency since 2021.
Return on Assets (ROA)
The return on assets mirrored the patterns seen in net profit margin and asset turnover with notable volatility. ROA rose sharply from 20.47% in 2020 to 31.75% in 2021, signaling a period of high profitability relative to assets. However, it then declined significantly over the subsequent years, falling to 14.85% in 2022 and further declining to just under 12% in both 2023 and 2024. This decline indicates diminished effectiveness in generating returns from the company’s asset base in recent years.
Overall Insights
The year 2021 stands out as an exceptional year with peak profitability and asset efficiency. Following this peak, the company experienced declines in profitability, asset utilization, and returns, stabilizing at lower levels by 2023 and 2024. The decrease in both asset turnover and return on assets suggests challenges in asset management or external factors impacting operational efficiency. Despite these declines, net profit margins remain relatively high, indicating ongoing profitability albeit at a reduced level compared to the peak year.

Four-Component Disaggregation of ROA

Regeneron Pharmaceuticals Inc., decomposition of ROA

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2024 11.69% = 0.92 × 0.99 × 34.05% × 0.38
Dec 31, 2023 11.95% = 0.94 × 0.98 × 32.57% × 0.40
Dec 31, 2022 14.85% = 0.89 × 0.99 × 40.40% × 0.42
Dec 31, 2021 31.75% = 0.87 × 0.99 × 58.38% × 0.63
Dec 31, 2020 20.47% = 0.92 × 0.99 × 45.51% × 0.50

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Tax Burden
The tax burden ratio exhibits some fluctuations over the analyzed period. It decreased from 0.92 in 2020 to a low of 0.87 in 2021, indicating a reduction in tax expenses relative to pre-tax income during that year. Subsequently, it increased to 0.94 in 2023 before slightly declining again to 0.92 in 2024, suggesting variability in the company's effective tax rate without a clear upward or downward trend.
Interest Burden
The interest burden ratio remains relatively stable throughout the period, consistently around 0.98 to 0.99. This stability implies that interest expenses have had a minimal and steady impact on earnings before taxes, indicating effective management of debt-related costs or low levels of interest-bearing liabilities.
EBIT Margin
The EBIT margin shows significant volatility across the years. It peaked in 2021 at 58.38%, indicating a strong earnings performance relative to revenue during that year. However, this margin declined considerably in subsequent years, dropping to 40.4% in 2022 and further to the low 30s in 2023 and 2024, signaling decreasing operating profitability despite revenue generation.
Asset Turnover
Asset turnover demonstrates a declining trend after an initial increase. Starting at 0.5 in 2020, it rose to 0.63 in 2021, reflecting greater efficiency in using assets to generate sales. Nonetheless, from 2022 onward, the ratio declined consecutively to 0.42, 0.4, and 0.38 by 2024, indicating reduced efficiency in the utilization of assets to produce revenue.
Return on Assets (ROA)
The return on assets mirrors the trends in EBIT margin and asset turnover. It increased markedly from 20.47% in 2020 to 31.75% in 2021, reflecting improved overall profitability with efficient asset use and operational performance. After 2021, ROA declined sharply to 14.85% in 2022 and continued a downward trajectory to approximately 11.7% by 2024, signaling waning ability to generate profit from the company’s asset base.

Disaggregation of Net Profit Margin

Regeneron Pharmaceuticals Inc., decomposition of net profit margin ratio

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2024 31.07% = 0.92 × 0.99 × 34.05%
Dec 31, 2023 30.14% = 0.94 × 0.98 × 32.57%
Dec 31, 2022 35.64% = 0.89 × 0.99 × 40.40%
Dec 31, 2021 50.25% = 0.87 × 0.99 × 58.38%
Dec 31, 2020 41.35% = 0.92 × 0.99 × 45.51%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Tax Burden
The tax burden ratio shows slight fluctuations over the five-year period, starting at 0.92 in 2020, dipping to a low of 0.87 in 2021, then gradually increasing to 0.94 in 2023 before slightly declining again to 0.92 in 2024. This indicates variability in the effective tax rate, with the highest tax burden occurring in 2023.
Interest Burden
The interest burden ratio remains relatively stable throughout the period, consistently near 0.99. There is a minor dip to 0.98 in 2023 but overall the burden from interest expense appears minimal and constant across the years, suggesting low and steady interest expenses relative to pre-interest earnings.
EBIT Margin
The EBIT margin exhibits notable volatility. Starting from a moderate 45.51% in 2020, it peaks significantly at 58.38% in 2021, then experiences a sharp decline to 40.4% in 2022. This downward trend continues in 2023 to 32.57%, followed by a modest recovery to 34.05% in 2024. The data suggests that operating profitability faced considerable pressure after 2021, though some improvement is observed in the latest year.
Net Profit Margin
The net profit margin follows a pattern similar to the EBIT margin. It rises from 41.35% in 2020 to a high of 50.25% in 2021, then declines markedly to 35.64% in 2022 and continues to fall to 30.14% in 2023. In 2024, a slight increase to 31.07% is noted. Overall, profitability after all expenses has declined since 2021, with a minor recovery evident at the end of the period.